Effect of the APOE-491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The Rotterdam Study (Q44063114)

29 November 2017

title

Effect of the APOE-491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The Rotterdam Study (English)

1 reference

29 November 2017

0 references

Cornelia M. van Duijn

10

object named as

van Duijn CM

1 reference

29 November 2017

7

Hofman A

1 reference

29 November 2017

8

Breteler MM

1 reference

Christine Van Broeckhoven

29 November 2017

9

object named as

Van Broeckhoven C

1 reference

29 November 2017

Roks G

1

1 reference

29 November 2017

Cruts M

2

1 reference

29 November 2017

Houwing-Duistermaat JJ

3

1 reference

29 November 2017

Dermaut B

4

1 reference

29 November 2017

Serneels S

5

1 reference

29 November 2017

Havekes LM

6

1 reference

29 November 2017

publication date

1 July 2002

1 reference

American Journal of Medical Genetics Part A

29 November 2017

published in

1 reference

29 November 2017

volume

114

1 reference

29 November 2017

issue

5

1 reference

29 November 2017

page(s)

570-573

1 reference

The -491A/T polymorphism of the Apolipoprotein E gene is associated with the ApoEepsilon4 allele and Alzheimer's disease

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. The EARS Study. European Atherosclerosis Research Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Promoter polymorphism (-491A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Determinants of disease and disability in the elderly: The Rotterdam elderly study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Incidence and risk of dementia. The Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

The -491 A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Genetic epidemiology of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Apolipoprotein E promoter polymorphism and sporadic Alzheimer's disease in a Japanese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Cholesterol determinations. A comparative study of methods with special reference to enzymatic procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations--the ECTIM Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Apolipoprotein E promoter and alpha2-macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Confidence interval estimation of interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

Apolipoprotein E4 allele in a population–based study of early–onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.10407

21 January 2018

Identifiers

DOI

10.1002/AJMG.10407

1 reference

29 November 2017

1 reference